|
2026
|
G/S
|
Pharmaceutical preparations for use in oncology; Pharmaceutical preparations for the treatment of... |
|
|
G/S
|
Pharmaceutical preparations and substances. |
|
|
G/S
|
Pharmaceutical preparations for the treatment of diseases and disorders of the cardiovascular, re... |
|
|
G/S
|
Pharmaceutical preparations and substances. |
|
|
G/S
|
Pharmaceutical preparations for use in oncology; Pharmaceutical preparations and substances for t... |
|
2025
|
Invention
|
Combination comprising capivasertib and abiraterone for treating pten-deficient metastatic hormon... |
|
|
Invention
|
Vaccine. The present disclosure relates to an mRNA molecule encoding a polypeptide comprising an ... |
|
|
Invention
|
Compounds and methods for reducing arhgef6 expression. Provided are oligonucleotides, polynucleot... |
|
|
Invention
|
Bispecific t-cell engager molecule combinations for use in treatment of claudin18.2 expressing so... |
|
|
Invention
|
Dosage regimens for azd5004. The specification relates to the administration of small molecule, o... |
|
|
Invention
|
Methods of treating diabetes. The specification relates to the administration of small molecule, ... |
|
|
Invention
|
Methods of treating or managing obesity. The specification relates to the administration of small... |
|
|
Invention
|
Glp1r agonist and sglt-2 inhibitor combination therapy. The specification relates to the co- admi... |
|
|
Invention
|
Glp1r agonist and pcsk9 inhibitor combination therapy. The specification relates to the co- admin... |
|
|
Invention
|
Azd5004 for use in treating inflammatory disorders or autoimmune disorders. The specification rel... |
|
|
Invention
|
Use of inhibitors or modulators of artemis in gene editing. The present disclosure provides modul... |
|
|
Invention
|
Conjugates comprising linkers. The specification relates to conjugates comprising a linker of For... |
|
|
Invention
|
Conjugates comprising cleavable linkers. The specification relates to conjugates of Formula (I) a... |
|
|
Invention
|
Combination of zibotentan and dapagliflozin for the treatment of chronic kidney disease and liver... |
|
|
Invention
|
Jak1 selective inhibitors.
Disclosed herein are compounds of Formula (I),
Disclosed herein are... |
|
|
Invention
|
Double-stranded rnai agents and compositions for reducing expression of angiopoietin-like 3 (angp... |
|
|
Invention
|
Substituted indazoles as irak4 inhibitors.
The present application relates to chemical compounds... |
|
|
Invention
|
Liquid-phase oligonucleotide synthesis using 2-(2-nitrophenyl)propyloxycarbonyl (nppoc) as a prot... |
|
|
Invention
|
Treatment of cancer with therapeutic binding molecules. A method of treating cancer in a subject ... |
|
|
Invention
|
Therapeutic combinations of an akt inhibitor, a bcl-2 inhibitor, and a glucocorticoid. Therapeuti... |
|
|
Invention
|
Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase ... |
|
|
Invention
|
Reusable auto-injector. Described herein is an auto-injector for receiving and operating a casset... |
|
|
Invention
|
Chemical compounds.
The present invention relates to azaquinolone compounds of Formula (I), and ... |
|
|
Invention
|
Carboxamide compounds as pkmyt1 inhibitors. Compounds having the structure of Formula (1) and pha... |
|
|
Invention
|
Quinazoline derivatives as gipr antagonists. The present specification relates to compounds of for... |
|
|
Invention
|
Improved cas9 proteins. The disclosure relates to a Cas9 protein comprising a polypeptide sequenc... |
|
|
Invention
|
Combination therapy comprising durvalumab and cisplatin/gemcitabine for use in treating bladder c... |
|
|
Invention
|
Methods, combinations, and uses for the treatment of muscle invasive bladder cancer.
The disclos... |
|
|
Invention
|
Therapies for wound treatment. The present specification concerns therapeutic approaches for the ... |
|
|
Invention
|
Irak4 inhibitors.
The present application relates to chemical compounds of Formula (I), and phar... |
|
2024
|
Invention
|
Medical injector |
|
|
Invention
|
Inhaler |
|
2023
|
Invention
|
Treatment of lupus.
The disclosure relates to methods and compositions for the treatment of syst... |
|
|
Invention
|
Compositions and methods for treating advanced solid tumors.
Disclosed are methods for treating ... |
|
|
Invention
|
Combination of sglt2 inhibitors and mineralcorticoid receptor modulators for use in treatment of ... |
|
|
Invention
|
Mta-cooperative prmt5 inhibitors for use in the treatment of cancer.
The present specification r... |
|
|
Invention
|
Methods for detecting metabolites using a microfluidic-based ce-ms system.
The present disclosur... |
|
|
Invention
|
Epidermal growth factor receptor tyrosine kinase inhibitors in combination with hgf-receptor inhi... |
|
|
Invention
|
Anti-pcrv and psl bispecific antibodies for treatment of bronchiectasis.
This disclosure relates... |
|
|
Invention
|
N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-quinoline-4-carboxamides.
Compounds having the struct... |
|
|
Invention
|
Solid-state forms of n-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-morpholinoquinoline-4-carboxami... |
|
|
Invention
|
Systems and methods for end to end continuous downstream processing.
Provided herein are methods... |
|
|
Invention
|
Recombinant virus expressing interleukin-12.
The present disclosure relates to a recombinant pox... |
|
|
Invention
|
Rxfp1 modulators for treating resistant hypertension or heart failure with pulmonary hypertension... |
|
|
Invention
|
Combinations of rxfp1 modulators and sglt2 inhibitors.
The specification generally relates to co... |
|
2022
|
Invention
|
Therapeutic combinations of capivasertib and venetoclax.
Therapeutic combinations of capivaserti... |
|
|
Invention
|
Novel lipids for delivery of nucleic acid segments.
Disclosed herein are compounds of Formula (I... |
|
|
Invention
|
Compositions and methods for delivering a macromolecule to a cell.
Compounds and methods are pro... |
|
2018
|
Invention
|
Jak1 selective inhibitors |
